Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Druggability Technologies Appoints Louis Scotti as Chief Business Development Officer

Abstract:
Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, today announced the appointment of Louis Scotti to the newly created position of Chief Business Development Officer. Mr. Scotti will be responsible for all business development activities and managing the company's numerous existing collaborations for its NanoActive™ technology platform, which significantly improves the solubility, permeability and pharmacokinetics of diverse chemical and biological compounds.

Druggability Technologies Appoints Louis Scotti as Chief Business Development Officer

Dublin, Ireland | Posted on August 3rd, 2012

"We are pleased that Mr. Scotti has joined our senior management team at DRGT," said Gabor Heltovics, CEO of DRGT. "With his long track record of concluding major drug development collaborations with pharmaceutical and biotechnology companies worldwide, Mr. Scotti will be an integral part of our efforts to expand the successful application of our proprietary technologies."

Mr. Scotti most recently served in senior commercial roles during a 12-year career at Arena Pharmaceuticals, Inc., a NASDAQ listed company that recently received FDA approval of Belviq® (lorcaserin HCl), the first prescription weight-loss treatment approved by FDA in 13 years. At Arena, Mr. Scotti held several positions, including Vice President Business Development, Vice President Marketing & Business Development and Vice President Commercial Planning. He was directly responsible for corporate alliances with major pharmaceutical companies such as Merck, J&J and Eli Lilly. Previously, Mr. Scotti was CEO of ProtoMed, Inc. and earlier headed licensing activities as executive director for Ligand Pharmaceuticals, Inc. Mr. Scotti holds a B.S.E. in biomedical engineering from the University of Pennsylvania.

####

About Druggability Technologies Holdings Limited (DRGT)
Headquartered in Dublin, Ireland, DRGT, through its subsidiaries, is developing and commercializing its proprietary NanoActive™ high throughput technology platform. This platform delivers significant improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds.

The Company's experience in improving the bioavailability and kinetic profile of drugs is born of a heritage of three decades of scientific and industrial knowledge gained through successful commercial ventures in bio- and chemo-informatics, combinatorial chemistry, chemical genomics, flow chemistry, colloidal chemistry, and nanotechnology.

For more information, please click here

Contacts:
Druggability Technologies Holdings Ltd.
Gabor Heltovics
Chief Executive Officer
+36-1-8808-468
+36-1-8808-501 (FAX)

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Switching with molecules: Molecular switch will facilitate the development of pioneering electro-optical devices May 25th, 2018

Tunable diamond string may hold key to quantum memory: A process similar to guitar tuning improves storage time of quantum memory May 24th, 2018

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

2018 Kavli Prizes in Astrophysics, Nanoscience, and Neuroscience to be Announced Live on May 31: Live announcement at the Norwegian Academy of Science and Letters to be streamed live at World Science Festival Event May 24th, 2018

Nanomedicine

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Elastic microspheres expand understanding of embryonic development and cancer cells May 15th, 2018

Nanomedicine -- Targeting cancer cells with sugars May 14th, 2018

Announcements

Switching with molecules: Molecular switch will facilitate the development of pioneering electro-optical devices May 25th, 2018

Tunable diamond string may hold key to quantum memory: A process similar to guitar tuning improves storage time of quantum memory May 24th, 2018

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

2018 Kavli Prizes in Astrophysics, Nanoscience, and Neuroscience to be Announced Live on May 31: Live announcement at the Norwegian Academy of Science and Letters to be streamed live at World Science Festival Event May 24th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Jim Barnhart Joins Nanometrics as Senior Vice President of Operations March 15th, 2018

Jonathan Chou to Join Nanometrics as Chief Financial Officer February 26th, 2018

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Leti’s New CEO November 28th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project